<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">11384092</article-id><article-id pub-id-type="pmc">2363656</article-id><article-id pub-id-type="pii">6691841</article-id><article-id pub-id-type="doi">10.1054/bjoc.2001.1841</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Feasibility of intraventricular administration of etoposide in patients with metastatic brain tumours</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Fleischhack</surname><given-names>G</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Reif</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Hasan</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Jaehde</surname><given-names>U</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Hettmer</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Bode</surname><given-names>U</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Paediatric Haematology/Oncology, University of Bonn, Adenauerallee 119 Bonn, D-53113</aff><aff id="aff2"><label>2</label>Department of Clinical Pharmacy, Institute of Pharmacy, Free University of Berlin, Kelchstrasse 31, D-12169 Berlin</aff><aff id="aff3"><label>3</label>Department of Clinical Pharmacy, Institute of Pharmacy, University of Bonn, An der Immenburg 4, D-53121 Bonn, Germany</aff><pub-date pub-type="ppub"><month>06</month><year>2001</year></pub-date><volume>84</volume><issue>11</issue><fpage>1453</fpage><lpage>1459</lpage><history><date date-type="received"><day>04</day><month>07</month><year>2000</year></date><date date-type="rev-recd"><day>20</day><month>02</month><year>2001</year></date><date date-type="accepted"><day>19</day><month>03</month><year>2001</year></date></history><copyright-statement>Copyright 2001, Cancer Research Campaign</copyright-statement><copyright-year>2001</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>As the systemic administration of etoposide is effective in the treatment of relapsed and metastatic brain tumours, a pilot trial was designed to study the feasibility of intraventricular administration of etoposide in such patients. 14 patients aged 2.1 to 33.2 years were treated with intraventricular etoposide simultaneously with either oral or intravenous chemotherapy with trofosfamide or carboplatin and etoposide. In 59 courses (1&#x02013;12/patient) 0.5&#x02008;mg etoposide was administered daily via an indwelling subcutaneous reservoir for 5 consecutive days every 2&#x02013;5 weeks over a period of 0&#x02013;11 months. During 15 courses in 5 patients serial CSF samples were obtained and etoposide levels were determined by reversed-phase HPLC. Side effects included transient headache and bacterial meningitis, each during 2 courses. Pharmacokinetic data analysis in the CSF (11 courses, 4 patients) revealed a terminal half-life of 7.4&#x000b1;1.2 hours and an AUC of 25.0 &#x000b1; 9.5&#x02008;&#x003bc;g h ml<sup>&#x02013;1</sup>(mean &#x000b1; standard deviation). The volume of distribution at steady state and total clearance exhibited a large interindividual variability with mean values of 0.16&#x02008;l and 0.46&#x02008;ml min<sup>&#x02013;1</sup>respectively. Intraventricularly administered etoposide is well tolerated. CSF peak levels exceed more than 100-fold those achieved with intravenous infusions. Further studies should be focused on optimizing the dose and schedule and on determining the effectiveness of intraventricularly administered etoposide. &#x000a9; 2001 Cancer Research Campaign <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.bjcancer.com">http://www.bjcancer.com</ext-link></p></abstract><kwd-group><kwd>etoposide</kwd><kwd>intraventricular therapy</kwd><kwd>metastatic medulloblastoma</kwd><kwd>pharmacokinetics</kwd></kwd-group></article-meta></front></article>


